I&D: IV infusion,
Non-Hodgkin's Lymphoma, CD20-positive:
Diffuse large B-cell & Follicular B-cell, in combination for first-line treatment: 375 mg/m2 on day 1 of each anthracycline-containing or CVP(cyclophosphamide, vincristine, and prednisone) C/T cycle, for up to 8 cycles.
Low-grade B-cell, stable or responsive to prior CVP C/T: 375 mg/ m2 given once wkly for 4 doses q 6 mo for up to 16 doses.
Relapsed or refractory, low-grade or follicular B-cell: single agent, 375 mg/ m2 once wkly for 4-8 doses; may retreat with additional 4 doses with progressive disease.
Note: Premedicate before each infusion with acetaminophen and an antihistamine, consider TLS prophylaxis in patients at high-risk.
Rheumatoid arthritis (Moderate to Severe), In combination with MTX, in patients who had an inadequate response to one or more tumor-necrosis-factor antagonist therapies: 1000 mg IV followed by a second 1000 mg IV dose 2 wk later; no more often than q16wk; Max. a total of 2 doses; used in combination with MTX.
Note: premedication: administer a glucocorticoid 30 min prior to each infusion (such as methylprednisolone 100 mg IV or its equivalent) and with acetaminophen and an antihistamine |
